PP
HZNP

PDT Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

PDT Partners’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-57,763
Closed -$4.61M – 1169
2022
Q2 		$4.61M Sell
57,763
-22,111
-28% -$2.09M 0.41% 24
2022
Q1 		$8.4M Buy
79,874
+18,297
+30% +$1.78M 0.72% 6
2021
Q4 		$6.64M Buy
61,577
+52,477
+577% +$5.72M 0.51% 11
2021
Q3 		$997K Sell
9,100
-709
-7% -$73.6K 0.07% 342
2021
Q2 		$919K Buy
+9,809
New +$903K 0.06% 390
2019
Q2 		– Sell
-132,700
Closed -$3.51M – 504
2019
Q1 		$3.51M Sell
132,700
-59,500
-31% -$1.41M 0.2% 144
2018
Q4 		$3.76M Buy
192,200
+29,500
+18% +$578K 0.21% 141
2018
Q3 		$3.19M Sell
162,700
-38,700
-19% -$736K 0.13% 188
2018
Q2 		$3.33M Buy
+201,400
New +$3.07M 0.13% 195
2016
Q3 		– Sell
-315,800
Closed -$5.2M – 534
2016
Q2 		$5.2M Buy
315,800
+88,900
+39% +$1.44M 0.41% 118
2016
Q1 		$3.76M Buy
+226,900
New +$3.97M 0.24% 177
2015
Q4 		– Sell
-61,950
Closed -$1.23M – 1138
2015
Q3 		$1.23M Sell
61,950
-58,237
-48% -$1.84M 0.03% 654
2015
Q2 		$4.17M Buy
120,187
+21,857
+22% +$667K 0.11% 234
2015
Q1 		$2.55M Buy
+98,330
New +$1.8M 0.06% 379
2014
Q4 		– Sell
-68,700
Closed -$844K – 1245
2014
Q3 		$844K Buy
68,700
+37,100
+117% +$431K 0.02% 751
2014
Q2 		$500K Hold
31,600
– – 0.01% 1008
2014
Q1 		$478K Sell
31,600
-26,700
-46% -$302K 0.01% 972
2013
Q4 		$444K Buy
+58,300
New +$314K 0.05% 462

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

PDT Partners's HZNP Position: Q3 2022 in Review

PDT Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 57,763 shares — an estimated $4.61M sold.

PDT Partners first reported a position in HZNP in Q4 2013 and held it in 18 quarters. The position peaked at $8.4M in Q1 2022. 529 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

  • PDT Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
  • PDT Partners sold 57,763 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $4.61M.
  • PDT Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2013 and held it in 18 quarters.
  • PDT Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $8.4M in Q1 2022.
  • 529 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on PDT Partners's 13F filing for Q3 2022, filed 14 Nov 2022.